• PDF / 169,651 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 91 Downloads / 141 Views

DOWNLOAD

REPORT

---

1 S

Lack of efficacy: 5 case reports In a prospective study of 120 patients underwent liver transplantation between 1990 and 2013 for hepatitis C virus infection; five patients (3 women and 2 men) aged 50–64 years were described; who exhibited lack of efficacy following treatment with ribavirin and/or sofosbuvir for hepatitis C virus recurrence [dosages not stated]. The patients, who underwent liver transplantation and had hepatitis C virus recurrence with/without hepatocellular carcinoma started receiving direct-acting antiviral treatment with oral ribavirin (3 patients), and oral sofosbuvir and oral ribavirin (2 patients). The 3 patients who had hepatitis C virus genotype 1b (n=2) or genotype 1 (n=1), received ribavirin, whereas the 2 patients who had hepatitis C virus genotype 3 received sofosbuvir and ribavirin. The recurrence of hepatitis C virus infection in all patients were confirmed by HCV viraemia with quantitative polymerase chain reaction. All these five patients had been previously treated with unspecified interferon. Out of the five patients, four patients had hepatocellular carcinoma before liver transplantation. The antiviral treatment of sofosbuvir and ribavirin was given for 24 weeks in patients with hepatitis C virus genotype 3. The failure of antiviral treatment with ribavirin and/or sofosbuvir for hepatitis C virus recurrence was noted in all five patients. Cieciura T, et al. Hepatocellular Carcinoma Is a Negative Predictor of Sustained Viral Response in Liver Transplant Recipients With Hepatitis C Treated With Direct-Acting 803519697 Antivirals. Transplantation Proceedings 52: 2450-2453, No. 8, Oct 2020. Available from: URL: http://doi.org/10.1016/j.transproceed.2020.01.098

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Dec 2020 No. 1833